A Pilot Study of Romosozumab in Postmenopausal Women with Myeloma-Related Bone Disease and Osteoporosis (IMS 2026) - Sep 11, 2026 - Abstract #PA-009; Pres time: Sep 24, 2026; "During romo therapy, 4 were on maintenance therapy, 5 on daratumumab-based regimens with 2 proceeding to CART, and 1 on observation...All pts had prior zoledronic acid (ZA) with median time from last dose of ZA to romo start of 22 (range 4-58) mos... In our study, romo was well-tolerated and resulted in significant early increases in bone formation markers (P1NP, osteocalcin, BAP) compared to baseline. Our findings suggest that romo has positive anabolic effects in MM pts without negatively impacting anti-MM therapy."
Clinical • Hematological Malignancies • Multiple Myeloma • Orthopedics • Osteoporosis • Rheumatology
|
|
Carlyn Tan1; Andriy Derkach1; David Nemirovsky1; Malin Hultcrantz1; Hani Hassoun1; Sham Mailankody1; Neha Korde1; Urvi A. Shah1; Sridevi Rajeeve1; Kylee Maclachlan1; Hamza Hashmi1; Maximilian Merz1; Francesco Maura1; Ross Firestone1; Gunjan Shah1; Eric Jurgens1; Michael Scordo1; Heather Landau1; Sergio Giralt1; Alexander Lesokhin1; Adrianna Herskovits1; Heiko Schoder1; Burcin Agridag Ucpinar1; Saad Z. Usmani1; Azeez Farooki1
|